Announced Wed, 1 Jul · 21:53 IST
Lupin Gets U.S. FDA EIR for Somerset Facility with VAI Classification
Compliance View source PDF
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.5%1-day move
₹2396.30
prior close
₹2420.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-0.9-0.7-1.0+3.5+3.9+3.9+2.6+4.6+3.8+0.1———
Up moveDown movePending
AI summary
Lupin received the Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset, New Jersey manufacturing facility with a Voluntary Action Indicated (VAI) classification. The inspection took place from April 13 to April 17, 2026. VAI is a satisfactory regulatory outcome indicating the facility is in acceptable compliance and no mandatory corrective action is required from the FDA.
Likely market impact
Positive outcome. VAI classification confirms acceptable compliance at the U.S. facility, easing regulatory uncertainty for investors.